Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03559426
Other study ID # 15/0947
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date March 24, 2016
Est. completion date March 10, 2022

Study information

Verified date May 2022
Source University College, London
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Psychosis and schizophrenia are common and costly mental health problems. Psychosis is the name given to a group of mental conditions in which cause people to perceive or interpret things differently from those around them. One of the most common causes of psychosis is schizophrenia, a condition that causes a range of psychological symptoms, including hallucinations (hearing and/or seeing things) and delusions (believing something that is not true). One of the main treatment options for psychosis and schizophrenia is long-term treatment with antipsychotic medication, but many patients still find life difficult. Antipsychotic drugs can also have dangerous and unpleasant side effects. Finding alternatives to long-term drug treatment is a priority for patients and services. This study is testing the effects of gradually reducing antipsychotic medication in people with schizophrenia, psychosis or similar conditions in order to see if it can help improve day-to-day functioning and how it affects their chance of suffering a relapse (worsening of their condition).


Description:

The RADAR trial is a randomised controlled trial that will compare a flexible and gradual strategy of antipsychotic reduction and possible discontinuation with maintenance antipsychotic treatment in people with schizophrenia or who have recurrent psychotic episodes. In the reduction group, a guideline reduction schedule will be devised by the research team for each participant taking into account starting dose and number of antipsychotics prescribed. This may be adjusted by treating clinicians in discussion with participants. Antipsychotics will be discontinued in cases where reduction progresses well. The reduction schedule will be flexible, and will include guidance on monitoring and treating symptoms and signs of early relapse. Participants will be individually randomised to the two treatment strategies, which will be administered by treating clinicians. They will be followed up for two years. The primary outcome is social functioning, and secondary outcomes include relapse, symptoms, side effects, employment and medication adherence.


Recruitment information / eligibility

Status Completed
Enrollment 253
Est. completion date March 10, 2022
Est. primary completion date March 10, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Aged over 18 years - A clinical and/or ICD10 diagnosis of schizophrenia, schizoaffective disorder, delusional disorder or other non-affective psychosis - More than one previous episode of relapse or psychotic exacerbation, or a single episode lasting more than one year - Taking antipsychotic medication Exclusion Criteria: - Participant lacks capacity to consent to the trial - Participant has insufficient command of spoken English to understand trial procedures - Participant subject to section 37/41 of the Mental Health Act (MHA) or a Community Treatment Order (CTO) that includes a requirement to take antipsychotic medication. - Clinician considers there will be a serious risk of harm to self or others - Participant has been admitted to hospital or had treatment from the Home Treatment or Crisis Team within the last month - Females who have a confirmed pregnancy - Females who are breast-feeding - Involvement in another "investigational medicinal product" (IMP) trial - No contraindications to continuing on antipsychotic medication

Study Design


Intervention

Drug:
Antipsychotic Reduction
Antipsychotic medication is gradually reduced and discontinued if possible. A flexible individualised antipsychotic reduction schedule is devised for each patient by the research team, based on the participant's initial antipsychotic regime. Antipsychotic dose is reduced incrementally every two months, with flexibility to speed up or slow down the schedule in discussion with the patient. The antipsychotic reduction extends over a period of between six to 12 months, although this may be extended according to individual circumstances.
Antipsychotic Maintenance
Participants continue to receive antipsychotic treatment at the original dose for the 24 month duration of the trial. Increases or minor adjustments to antipsychotic medication are permitted.

Locations

Country Name City State
United Kingdom University College London London UK

Sponsors (1)

Lead Sponsor Collaborator
University College, London

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Social Functioning Scale (Assessing change over time) Evaluates how the patient functions in daily living and social skills Baseline, 6 months, 12 months, 24 months
Secondary Severe relapse Severe relapse is defined as admission to hospital for a relapse of a psychotic condition. Duration of the trial follow-up (24 months)
Secondary Positive and Negative Syndrome Scale (PANSS) Assessing change over time Clinical assessment of current symptomology. Measure refers to prevalence of psychotic symptoms ranging from absent to extreme. Baseline, 6 months, 12 months, 24 months
Secondary Modified Glasgow Antipsychotics Side-Effects Scale (GASS) Assessing change over time Self-report measure of physical and mental side effects patient has experienced recently. Scale refers to prevalence of side effects from antipsychotic medication in the last week. Baseline, 6 months, 12 months, 24 months
Secondary Manchester Short Assessment of Quality of Life (MANSA) Assessing change over time Assessment of quality of life. Baseline, 6 months, 12 months, 24 months
Secondary Digit Span (forwards and backwards) Assessing change over time Neuropsychological assessment of short-term memory and attention Baseline,12 months, 24 months
Secondary Digit Symbol Coding (Assessing change over time) A neuropsychological assessment of motor skill and attention Baseline,12 months, 24 months
Secondary Rey Auditory Verbal Learning (Assessing change over time) Neuropsychological assessment of short-term memory and learning Baseline,12 months, 24 months
Secondary Trail Making Test (Assessing change over time) Neuropsychological assessment of motor skills Baseline,12 months, 24 months
Secondary Verbal Fluency (Assessing change over time) Neuropsychological assessment of language and communication skills Baseline,12 months, 24 months
Secondary Demographic Information Demographic data about the participant Baseline
Secondary Client Service Receipt Inventory (CSRI) Assessing change over time Economic measure of health service use including frequency services are used (inc. mental health, physical health, criminal justice, council activities) and medication currently used (inc. measuring dosage, frequency, medication name, and how long its been taken for) Baseline, 12 months, 24 months
Secondary Schedule for Economic Data from Patient Records Health information from patient notes to inform economic analysis Baseline, 12 months, 24 months
Secondary Questionnaire about the Process of Recovery (QPR) Assessing change over time Evaluates how participants view their recovery Baseline, 6 months, 12 months, 24 months
Secondary Work Productivity and Activity Questionnaire (WPAI) Assessing change over time Measure of the effect of health problems on occupational functioning (i.e. ability to work and perform normal daily activities) Baseline, 6 months, 12 months, 24 months
Secondary Relapse Questionnaire (Assessing change over time) Self-report measure of any recent experience of what the patient or their close ones would describe as a relapse (severe or non-severe). Developed for this trial to identify instances of severe and non-severe relapse. 6 months, 12 months, 24 months
Secondary Medication Adherence Rating Scale (MARS-5) Assessing change over time Self-report measure of how participant is currently using antipsychotic medication (medication adherence) Baseline, 6 months, 12 months, 24 months
Secondary Client Satisfaction Questionnaire (CSQ 8) Assessing change over time Patient satisfaction with mental health services. Baseline, 6 months, 12 months, 24 months
Secondary EQ-5D-5L (Euroqol five levels- Assessing change over time) Measure of health status Baseline, 6 months, 12 months, 24 months
Secondary ICECAP-A (ICEpop CAPability measure for Adults) Assessing change over time Measure of quality of life Baseline, 6 months, 12 months, 24 months
Secondary Arizona Sexual Experiences Scale (ASEX) Assessing change over time Evaluates sexual functioning Baseline, 6 months, 12 months, 24 months
See also
  Status Clinical Trial Phase
Recruiting NCT05039489 - A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia N/A
Completed NCT05111548 - Brain Stimulation and Cognitive Training - Efficacy N/A
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Completed NCT04503954 - Efficacy of Chronic Disease Self-management Program in People With Schizophrenia N/A
Completed NCT02831231 - Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium Phase 1
Completed NCT05517460 - The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center N/A
Completed NCT03652974 - Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy Phase 4
Recruiting NCT04012684 - rTMS on Mismatch Negativity of Schizophrenia N/A
Recruiting NCT04481217 - Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia N/A
Completed NCT00212784 - Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) Phase 3
Completed NCT04092686 - A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia Phase 3
Completed NCT01914393 - Pediatric Open-Label Extension Study Phase 3
Recruiting NCT03790345 - Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics Phase 2/Phase 3
Recruiting NCT05956327 - Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training N/A
Terminated NCT03261817 - A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders N/A
Terminated NCT03209778 - Involuntary Memories Investigation in Schizophrenia N/A
Completed NCT02905604 - Magnetic Stimulation of the Brain in Schizophrenia or Depression N/A
Recruiting NCT05542212 - Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia N/A
Completed NCT04411979 - Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia N/A
Terminated NCT03220438 - TMS Enhancement of Visual Plasticity in Schizophrenia N/A

External Links